Logo

Innovent and Eli Lilly Present Results of P-Ib Study of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) for Advanced Hepatocellular Carcinoma at ASCO GI 2022

Share this
Innovent and Eli Lilly Present Results of P-Ib Study of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) for Advanced Hepatocellular Carcinoma at ASCO GI 2022

Innovent and Eli Lilly Present Results of P-Ib Study of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) for Advanced Hepatocellular Carcinoma at ASCO GI 2022

Shots:

  • The P-Ib study included dose-escalation & expansion stages evaluates sintilimab (200mg) + bevacizumab biosimilar in 50 patients with LA or metastatic HCC
  • The results showed the 34% ORR (17/50) & (31% & 38%) for 7.5/15mg/kg (low/high-dose), 78% DCR (39/50), PFS (10.5mos.), m-OS (20.2mos.). In biomarker analysis, patients with a high level of CD137 ≥ 31.8 pg/mL have longer PFS with m-PFS (14.2mos. vs 4.1mos.), mOS (NR vs 15.6mos.) & TiME analysis showed that the high density of M1 macrophages in the stroma was related to higher efficacy, longer PFS & OS
  • The safety profile was consistent with previously reported studies of sintilimab & bevacizumab biosimilar with no new safety signals

Ref: PR Newswire | Image:Innovent

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions